PriceTargets.com logo

NASDAQ:VCEL - Vericel Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.00
  • Forecasted Upside: -3.27 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$51.69 As of 09/17/2021 01:00 AM ET
▲ +2.14 (4.32%)

This chart shows the closing price for VCEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vericel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCEL

Analyst Price Target is $50.00
▼ -3.27% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Vericel in the last 3 months. The average price target is $50.00, with a high forecast of $65.00 and a low forecast of $31.00. The average price target represents a -3.27% upside from the last price of $51.69.

This chart shows the closing price for VCEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Vericel. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2021SVB LeerinkLower Price TargetOutperform$67.00 ➝ $62.00High
6/30/2021OppenheimerReiterated RatingHoldHigh
5/6/2021HC WainwrightBoost Price TargetBuy$60.00 ➝ $65.00High
2/25/2021HC WainwrightBoost Price TargetBuy$44.00 ➝ $60.00Medium
2/25/2021SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $60.00Medium
2/22/2021BTIG ResearchBoost Price Target$45.00 ➝ $56.00High
2/16/2021TruistBoost Price Target$40.00 ➝ $60.00Low
1/25/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$37.00 ➝ $45.00High
1/19/2021LADENBURG THALM/SH SHBoost Price TargetBuy$27.50 ➝ $44.00Low
1/12/2021HC WainwrightBoost Price TargetBuy$26.00 ➝ $44.00High
1/11/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
1/5/2021BTIG ResearchBoost Price TargetBuy$30.00 ➝ $37.00N/A
12/17/2020StephensInitiated CoverageOverweight$31.00Low
10/19/2020BTIG ResearchBoost Price TargetBuy$23.00 ➝ $30.00High
10/15/2020HC WainwrightBoost Price TargetBuy$22.00 ➝ $26.00Low
10/12/2020SVB LeerinkBoost Price TargetOutperform$20.00 ➝ $30.00Medium
10/5/2020OppenheimerReiterated RatingBuy$32.00Medium
9/23/2020BTIG ResearchBoost Price TargetBuy$21.00 ➝ $23.00Medium
9/21/2020OppenheimerReiterated RatingBuy$32.00High
9/17/2020TruistInitiated CoverageBuy$24.00 ➝ $24.00Low
9/9/2020BTIG ResearchReiterated RatingBuy$21.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$22.00High
8/5/2020Needham & Company LLCInitiated CoverageHoldHigh
8/5/2020OppenheimerReiterated RatingBuyMedium
7/9/2020BTIG ResearchReiterated RatingBuy$21.00Low
7/9/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020HC WainwrightReiterated RatingBuy$22.00Low
5/6/2020LADENBURG THALM/SH SHBoost Price TargetBuy$20.00 ➝ $22.00High
5/5/2020BTIG ResearchReiterated RatingBuy$21.00Low
5/5/2020Needham & Company LLCInitiated CoverageHoldLow
5/5/2020OppenheimerReiterated RatingBuy$32.00Low
4/3/2020BTIG ResearchLower Price TargetBuy$24.00 ➝ $21.00Medium
4/2/2020Needham & Company LLCReiterated RatingHoldLow
2/26/2020BTIG ResearchReiterated RatingBuy$24.00High
2/26/2020HC WainwrightReiterated RatingBuyHigh
2/3/2020HC WainwrightBoost Price TargetBuy$21.00 ➝ $22.00High
11/5/2019Needham & Company LLCReiterated RatingHoldHigh
10/9/2019HC WainwrightInitiated CoverageBuy$19.00Medium
8/12/2019BTIG ResearchSet Price TargetBuy$24.00High
5/8/2019OppenheimerBoost Price TargetOutperform$23.00 ➝ $32.00Low
2/28/2019Needham & Company LLCDowngradeBuy ➝ Hold$17.92Medium
1/29/2019OppenheimerInitiated CoverageOutperform$23.00Low
11/6/2018Needham & Company LLCBoost Price TargetBuy$18.00Medium
11/6/2018BTIG ResearchBoost Price TargetBuy$17.00 ➝ $20.00Medium
8/8/2018Needham & Company LLCLower Price TargetBuy$15.00 ➝ $14.00Low
8/7/2018BTIG ResearchReiterated RatingBuy$17.00High
7/16/2018LADENBURG THALM/SH SHUpgradeNeutral ➝ BuyLow
5/9/2018BTIG ResearchReiterated RatingBuy$17.00Low
4/4/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$15.00High
3/6/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$5.00 ➝ $15.00High
3/6/2018LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
3/5/2018BTIG ResearchReiterated RatingBuy ➝ Buy$8.00 ➝ $13.00High
3/5/2018Piper Jaffray CompaniesBoost Price TargetOverweight$14.00High
1/2/2018BTIG ResearchSet Price TargetBuy$8.00Low
1/2/2018Piper Jaffray CompaniesReiterated RatingOverweight$9.00High
10/2/2017BTIG ResearchSet Price TargetBuy$6.00Low
9/7/2017BTIG ResearchReiterated RatingBuy$6.00Medium
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$7.00High
8/9/2017BTIG ResearchSet Price TargetBuy$6.00High
6/20/2017BTIG ResearchInitiated CoverageBuy$6.00High
3/13/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$9.00 ➝ $6.00High
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$6.00N/A
12/14/2016Needham & Company LLCSet Price TargetBuy$9.00N/A
11/9/2016Needham & Company LLCLower Price TargetBuy$12.00 ➝ $9.00N/A
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 3 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/22/2021
  • 2 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Vericel logo
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $51.69
Low: $49.53
High: $51.83

50 Day Range

MA: $52.18
Low: $46.35
High: $59.75

52 Week Range

Now: $51.69
Low: $17.78
High: $68.94

Volume

1,101,400 shs

Average Volume

624,110 shs

Market Capitalization

$2.41 billion

P/E Ratio

287.18

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Vericel?

The following Wall Street analysts have issued research reports on Vericel in the last year: BTIG Research, HC Wainwright, LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., Stephens, SVB Leerink LLC, TheStreet, Truist, and Zacks Investment Research.
View the latest analyst ratings for VCEL.

What is the current price target for Vericel?

7 Wall Street analysts have set twelve-month price targets for Vericel in the last year. Their average twelve-month price target is $50.00, suggesting a possible downside of 3.3%. HC Wainwright has the highest price target set, predicting VCEL will reach $65.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $31.00 for Vericel in the next year.
View the latest price targets for VCEL.

What is the current consensus analyst rating for Vericel?

Vericel currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VCEL will outperform the market and that investors should add to their positions of Vericel.
View the latest ratings for VCEL.

What other companies compete with Vericel?

Other companies that are similar to Vericel include CRISPR Therapeutics, Neurocrine Biosciences, Acceleron Pharma, Vir Biotechnology, Beam Therapeutics, Fate Therapeutics, Exelixis, Denali Therapeutics, Twist Bioscience, Halozyme Therapeutics, Adaptive Biotechnologies, Adagio Therapeutics, Kodiak Sciences, Sana Biotechnology and Abcam.

How do I contact Vericel's investor relations team?

Vericel's physical mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (800) 556-0311 and its investor relations email address is [email protected] The official website for Vericel is www.vcel.com.